La Rioja pharmaceutical law 2026: what changes for pharmacists and clinical researchers

Key data

Pharmacists and clinical researchers operating in La Rioja must be aware of a regulatory change that directly affects how their participation in clinical trials is managed. The Bilateral Cooperation Commission between the General State Administration and the Autonomous Community of La Rioja reached an agreement on April 29, 2026 to resolve the competency conflict generated by the seventh additional provision of Law 7/2025, of September 9, on pharmaceutical care and organization in La Rioja.

The core of the conflict was clear: who has the authority to designate the pharmacist participating in a clinical trial? The La Rioja regulation created ambiguity that the State considered an invasion of its competencies. The agreement clarifies the doubt and obliges La Rioja to correct it by law.

What does this regulation establish?

The agreement published on June 8, 2026 in the BOE establishes three concrete regulatory consequences:

• Mandatory legislative modification: The Government of La Rioja must reform the seventh additional provision of Law 7/2025 to make clear that the authority to designate the pharmacist participating in clinical trials rests with the principal investigator.
• Subjection to state and European regulations: Such designation remains always subject to EU Regulation 536/2014 on clinical trials with medicines for human use, and to state regulations on pharmaceutical products.
• Recognition of autonomous authority: The authority of the competent general directorate of La Rioja to develop good dispensing practice protocols is expressly recognized.

The agreement is communicated to the Constitutional Court in accordance with article 33.2 of its Organic Law, concluding the controversy and preventing the State from filing a constitutional appeal.

Economic and operational impact

This agreement does not generate direct costs for companies or professionals, but it does have relevant operational consequences for those participating in clinical trials in La Rioja:

• Legal certainty recovered: Clinical trials in progress or in the design phase in La Rioja are no longer exposed to uncertainty about which regulation prevails in the designation of the pharmacist. This reduces the risk of challenges or administrative paralysis.
• Obligation for La Rioja to adapt regulations: The La Rioja Government must initiate the legislative process to modify Law 7/2025. Until that modification occurs, the agreed interpretation is the one that must be applied.
• Dispensing protocols: The competent general directorate of La Rioja may develop good dispensing practice protocols, which may involve new internal procedures for pharmacies and research centers.
• No Constitutional Court appeal: Avoiding a constitutional appeal eliminates years of legal uncertainty that would have affected the planning of clinical trials in the community.

Who does it affect?

• Principal investigators of clinical trials operating in La Rioja: formally assume the authority to designate the participating pharmacist.
• Pharmacists who participate or wish to participate in clinical trials in La Rioja: their designation now unequivocally depends on the principal investigator, not on an autonomous administrative body.
• Hospital and clinical research centers in La Rioja: must adapt their internal procedures to the new regulatory interpretation.
• Pharmaceutical industry promoting clinical trials in La Rioja: greater clarity on the regulatory framework applicable to the designation of pharmacists.
• Health administration of La Rioja: obligated to process the legislative modification of Law 7/2025 and to develop good dispensing practice protocols.
• Pharmacy colleges in La Rioja: must inform their members about the new framework for designation in clinical trials.

Practical example

A hospital in Logroño is designing a clinical trial with medicines for human use under the framework of EU Regulation 536/2014. The principal investigator of the trial needs to designate a hospital pharmacist to manage the dispensation of the investigational medicine.

Before the agreement, the wording of the seventh additional provision of Law 7/2025 raised doubts about whether that designation corresponded to the principal investigator or whether some body of the La Rioja health administration should intervene, which could delay the start of the trial or generate challenges.

After the agreement of April 29, 2026, the answer is unequivocal: the principal investigator designates the pharmacist, in accordance with EU Regulation 536/2014 and state regulations. The hospital can proceed without competency ambiguity, and the competent general directorate of La Rioja may also establish good dispensing practice protocols that the designated pharmacist must follow.

What should companies do now?

1. Review active clinical trial protocols in La Rioja: Verify that the designation of the participating pharmacist is attributed to the principal investigator, in accordance with EU Regulation 536/2014.
2. Update internal procedures: Hospital centers and trial sponsors must adjust their trial design documents to reflect the principal investigator's authority in pharmaceutical designation.
3. Monitor the legislative process for modifying Law 7/2025: The Government of La Rioja must modify the seventh additional provision. It is advisable to monitor when that reform is published to definitively update internal procedures.
4. Stay alert to new dispensing protocols: The competent general directorate of La Rioja will develop good dispensing practice protocols. Pharmacies and research centers must incorporate them when published.
5. Consult the Pharmacy College of La Rioja: To obtain specific guidance on how the new framework affects the daily practice of pharmacists participating in clinical trials.

Official source

Consult complete regulation in official source

Notice: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-12400